School of Life Sciences, Liaoning University, Shenyang 110036, China.
Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang 110122, China.
Int J Mol Sci. 2023 May 12;24(10):8642. doi: 10.3390/ijms24108642.
Various lung diseases endanger people's health. Side effects and pharmaceutical resistance complicate the treatment of acute lung injury, pulmonary fibrosis, and lung cancer, necessitating the development of novel treatments. Antimicrobial peptides (AMPs) are considered to serve as a viable alternative to conventional antibiotics. These peptides exhibit a broad antibacterial activity spectrum as well as immunomodulatory properties. Previous studies have shown that therapeutic peptides including AMPs had remarkable impacts on animal and cell models of acute lung injury, pulmonary fibrosis, and lung cancer. The purpose of this paper is to outline the potential curative effects and mechanisms of peptides in the three types of lung diseases mentioned above, which may be used as a therapeutic strategy in the future.
各种肺部疾病危害人们的健康。急性肺损伤、肺纤维化和肺癌的治疗因副作用和药物耐药性而变得复杂，这需要开发新的治疗方法。抗菌肽 (AMPs) 被认为是传统抗生素的可行替代品。这些肽具有广谱的抗菌活性和免疫调节特性。以前的研究表明，包括抗菌肽在内的治疗性肽对急性肺损伤、肺纤维化和肺癌的动物和细胞模型有显著影响。本文旨在概述肽在上述三种肺部疾病中的潜在治疗效果和作用机制，这可能成为未来的一种治疗策略。
